H. pylori Treatment Guidelines

Introduction to Guidelines

The European Helicobacter Pylori Study Group's Maastricht Consensus guidelines, first established in 1997, provide a comprehensive European consensus on H. pylori management, and have been updated multiple times, with the Maastricht V/Florence guidelines being the most recent 3, 4
The American College of Gastroenterology (ACG) published influential guidelines, most recently updated in 2024, providing evidence-based recommendations specific to North American resistance patterns, prioritizing bismuth quadruple therapy as first-line treatment due to clarithromycin resistance exceeding 15% in most North American regions 1, 2

The American College of Gastroenterology (ACG) recommends bismuth quadruple therapy as first-line treatment for H. pylori infection in North America, due to high clarithromycin resistance rates 1, 2
The Toronto Consensus, a Canadian guideline, recommends 14-day treatment durations for all first-line therapies, emphasizing the importance of sufficient treatment duration for effective eradication 1, 2
The American Gastroenterological Association (AGA) emphasizes antimicrobial stewardship principles in its guidelines, aiming for absolute cure rates ≥95% rather than comparative effectiveness 5, 1, 2

Current guidelines universally recommend 14-day treatment durations rather than 7-10 days, improving eradication by approximately 5% 1, 2
The shift from clarithromycin-based triple therapy to bismuth quadruple therapy reflects global clarithromycin resistance increases from 9% (1998) to >20% in most developed regions 1, 2

Local resistance data should guide treatment selection over generalized guideline recommendations, as geographic applicability and regional antibiotic susceptibility surveillance are crucial for effective treatment 1, 5, 2
Guideline vintage is critical, as pre-2017 guidelines often recommend 7-day regimens and clarithromycin-based triple therapy as first-line, which are now obsolete due to resistance patterns 1, 2